Lake Street Maintains Buy on BioLife Solns, Lowers Price Target to $25
Portfolio Pulse from jenniferd'souza@benzinga.com
Lake Street analyst Thomas Flaten maintains a 'Buy' rating on BioLife Solns (NASDAQ:BLFS) but has lowered the price target from $34 to $25.
August 09, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lake Street analyst maintains a 'Buy' rating on BioLife Solns but lowers the price target from $34 to $25.
The news is directly related to BioLife Solns. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term stock price. However, the overall impact is neutral as the 'Buy' rating suggests the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100